Use of high-level HBV replication transgenic mice for evaluating drugs treating hepatitis B virus / 中国病理生理杂志
Chinese Journal of Pathophysiology
; (12)1986.
Article
in Zh
| WPRIM
| ID: wpr-528856
Responsible library:
WPRO
ABSTRACT
AIM:
To study the high-level HBV replication transgenic mice for evaluation of drugs treating hepatitis B virus.METHODS:
The HBV transgenic mice were treated respectively with lamivudine,large dose recombinant hepatitis B protein vaccine,?-1b interferon,siRNA to evaluate their pharmacodynamics and mechanism of action.RESULTS:
HBV DNA titre was reduced significantly in transgenic mice which were treated with lamivudine(100 mg?kg-1?d-1),recombinant hepatitis B protein vaccine(HBsAg 6 ?g/mouse),?-1b interferon(50 ?g /mouse),respectively.Recombinant hepatitis B protein vaccine and ?-1b interferon promoted the level of IL-2 and IFN-? and increased the Elispot number of spleen cells secreting IFN-? in the treated transgenic mice.HBV transgenic mice were treated with RNAi expression vector pU6-siHBV against HBV through vena caudalis by hydrodynamics technique.Five days later,the level of serum HBsAg was reduced by 56.7% and the inhibition lasted at least 14 days.The HbcAg(+)cells were decreased obviously by immunohistochemistry detection in liver tissue,but the RNAi did not reduce the serum HBV DNA titre.CONCLUSION:
These inbreeding high-level HBV replication transgenic mice are reliable and feasible for evaluating the anti-HBV drugs and have its economical and convenient superiority.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Chinese Journal of Pathophysiology
Year:
1986
Type:
Article